Deep mutational scanning identifies SARS-CoV-2 Nucleocapsid escape mutations of currently available rapid antigen testsSARS-CoV-2 variants can disrupt the efficacy of rapid antigen tests. By developing a high-throughput mammalian surface display platform to measure direct binding of diagnostic antibodies, all possible Nucleocapsid point mutations in past, present, and future variants were evaluated for their potential to affect the performance of these diagnostics tests.SARS-CoV-2 variants can disrupt the efficacy of rapid antigen tests. By developing a high-throughput mammalian surface display platform to measure direct binding of diagnostic antibodies, all possible Nucleocapsid point mutations in past, present, and future variants were evaluated for their potential to affect the performance of these diagnostics tests.Filipp Frank, Meredith M. Keen, Anuradha Rao, Leda Bassit, Xu Liu, Heather B. Bowers, Anamika B. Patel, Michael L. Cato, Julie A. Sullivan, Morgan Greenleaf, Anne Piantadosi, Wilbur A. Lam, William H. Hudson, Eric A. Ortlundhttps://www.cell.com/cell/fulltext/S0092-8674(22)01044-3?rss=yeshttp://www.cell.com/cell/inpress.rssCellCell RSS feed.Wireless News CampaignAugust 27, 2022

Powered by WPeMatico